Baseline patient characteristics of the immunotherapy treated NSCLC cohorts
| Characteristic | YTMA471 cohort N (%) | H12O_ITX1 cohort N (%) |
| Total | 56 | 128 |
| Gender | ||
| Male | 28 (50) | 100 (78.1) |
| Female | 28 (50) | 28 (21.9) |
| Age | ||
| <70 years old | 30 (53.6) | 68 (53.1) |
| ≥70 years old | 26 (46.4) | 60 (46.9) |
| Smoking history | ||
| Active smoker | 10 (18) | 34 (26.6) |
| Former smoker | 44 (79) | 88 (68.7) |
| Never smoker | 2 (3.6) | 6 (4.7) |
| Histology | ||
| Adenocarcinoma | 41 (73) | 54 (42.2) |
| Large-cell carcinoma | – | 16 (12.5) |
| Squamous cell carcinoma | 9 (16) | 58 (45.3) |
| Adenosquamous carcinoma | 2 (3.6) | – |
| NSCLC-NOS | 4 (7.1) | – |
| Stage | ||
| III | 5 (8.9) | 5 (3.9) |
| IV | 51 (91.1) | 123 (96.1) |
| Actionable drivers | ||
| EGFR/ALK/ROS1/RET alterations | 1 (1.7) | 7 (5.4) |
| No EGFR/ALK/ROS1/RET alterations | 48 (85.7) | 63 (49.2) |
| Unknown genetic alterations | 7 (12.5) | 58 (45.3) |
| Central nervous system metastasis | ||
| Yes | 21 (38) | 24 (18.7) |
| No | 35 (62) | 104 (81.3) |
| Liver metastasis | ||
| Yes | 11 (20) | 25 (19.5) |
| No | 45 (80) | 103 (80.5) |
| LIPI score | ||
| Good | 9 (16.1) | 27 (21.1) |
| Intermediate | 22 (39.3) | 54 (42.2) |
| Poor | 3 (5.4) | 42 (32.8) |
| Unknown | 22 (39.3) | 5 (3.9) |
| PD-L1 TPS by IHC | ||
| ≥50% | 15 (26.8) | 32 (25) |
| 1%–49% | 20 (35.7) | 44 (34.4) |
| <1% | 11 (19.6) | 46 (36) |
| Not evaluable | 10 (17.9) | 6 (4.6) |
| Immunotherapy line | ||
| 1 | 39 (70) | 20 (15.6) |
| 2 | 14 (25) | 79 (61.7) |
| ≥3 | 3 (5.4) | 29 (12.5) |
| Type of immunotherapy | ||
| Chemotherapy +PD-1 axis blockade | 22 (39.3) | 0 |
| Dual PD-1 +CTLA4 blockade | 1 (1.8) | 0 |
| Other PD-1 axis-based combinations | 5 (8.9) | 0 |
| Single-agent PD-1 axis blockade | 28 (50) | 128 (100) |
| Best response to immunotherapy | ||
| Complete or partial response | 17 (33.5) | 22 (17.1) |
| Stable disease | 22 (39) | 32 (25) |
| Progressive disease | 15 (27) | 74 (57.8) |
| Not evaluable | 1 | 0 |
| Clinical benefit group | ||
| Clinical benefit | 36 (64.3) | 37 (28.9) |
| No clinical benefit | 19 (33.9) | 90 (70.3) |
| Not evaluable | 1 (1.8) | 1 (0.8) |
CTLA-4, cytotoxic T-lymphocytes-associated protein 4 ; IHC, immunohistochemistry; LIPI, Lung Immune Prognostic Index; NSCLC-NOS, non-small cell lung cancer not otherwise specified; PD-1, programmed cell death protein-1 ; PD-L1, programmed death-ligand 1 ; TPS, Tumor Proportion Score.